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ABSTRACT:
Neuroblastoma is an aggressive pediatric cancer originating embryonically from 
the neural crest. The heterogeneity of the disease, as most solid tumors, complicates 
diagnosis and treatment. In neuroblastoma this heterogeneity is well represented 
in both primary tumours and derived cell lines and has been shown to be driven by 
a population of stem-like tumour initiating cells. Resolving the molecular mediators 
driving the division of this population of cells may indicate effective therapeutic 
options for neuroblastoma patients. This study has determined that the atypical 
cyclin-like protein Spy1, recently indicated in driving symmetric division of glioma 
stem cells, is a critical factor in the stem-like properties of neuroblastoma tumor 
initiating cell populations. Spy1 activates Cyclin Dependent Kinases (CDK) in a manner 
that is unique from classical cyclins. Hence this discovery may represent an important 
opportunity to design CDK inhibitor drugs to uniquely target subpopulations of cells 
within these aggressive neural tumours.
INTRODUCTION
Neuroblastoma is the most common pediatric 
extracranial solid malignancy with 98% of patients 
diagnosed by the age of 10 [1]. The disease has an 
unpredictable clinical course and poor prognosis, with 
only 30% long-term survival [1]. Due to its origin in 
the migratory neural crest, neuroblastoma occurs in 
the peripheral nervous system arising in sympathetic 
ganglia and adrenal medulla [2-4]. The neural crest is a 
population of stem cells that derives from the neural tube 
during embryogenesis. Therefore, the transient embryonic 
structure of the tumours is reflected in the enormous 
genetic and phenotypic heterogeneity of neuroblastoma. 
Although an inherited genetic predisposition was 
shown in a small subset of patients, spontaneous genetic 
changes are the most frequently observed. This commonly 
includes activation of oncogenes like MYCN and H-Ras, 
gain or loss of alleles, and alternations in cell ploidy [5-
8]. Neuroblastoma tumours display diverse immature 
cell types such as neuroblasts and glial precursors and 
an array of heterogeneous cell types at different stages of 
differentiation. Accumulating in vitro and in vivo evidence 
suggests that alteration in cell cycle control may affect the 
stage of tumour differentiation and ultimately contribute 
to neuroblastoma pathogenesis [9]. Indeed those tumours 
with a poorly differentiated phenotype correlate negatively 
with clinical outcomes [9, 10]. In addition, self-renewing 
tumour initiating cells (TICs) were reported to correlate 
with refractory or relapse state following the initial 
good response to therapy observed in patients [11]. The 
neuroblastoma stem-like TICs were identified among the 
heterogeneous population in cultured human cell lines 
[12-14]. Interestingly, several groups demonstrated the 
three principle populations of neuroblastoma cells: the 
highly proliferative yet weakly tumourigenic N-cells, 
the crest derived non-neuronal S precursors and the 
I-type malignant and multipotent neural crest stem cells 
harbouring TIC potential [15]. The I-type cells express 
CD133 and c-kit stem cell marker proteins and are capable 
of self-renewal and forming rapidly growing tumours [13, 
16, 17]. Importantly, the pentaspan protein CD133 was 
shown to regulate cell proliferation and differentiation in 
neuroblastoma [17]. Proliferation and differentiation are 
under control of the cell cycle however what regulates 
the balance of these decisions in the three dominant 
populations of cells found in neuroblastoma remains to 
be determined. 
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Spy1 (Spdya; Speedy; Spy1A; RINGO), encoded by 
SPDYA gene, is a cell cycle regulator that controls CDK2 
activity and G1-S phase transition in a fashion unique 
from that established for the classical cyclin proteins. The 
Spy1-CDK2 complex does not require CDK activating 
kinase (CAK) -mediated phosphorylation on CDK2, 
and it is less sensitive to inhibitory phosphorylation by 
regulators such as p21Cip1 and p27Kip1 [18-21]. Thus, Spy1 
is able to override several known cell cycle checkpoints, 
including those imposed by DNA damage [22, 23]. Both 
CDK2 and p27Kip1 play an important role in neuroblastoma 
progression and patient prognosis [24-26]. Notably, p27Kip1 
accumulates in neuroblastoma cells treated with retinoids 
and necessitates neuronal differentiation [27], whereas 
increased CDK2 activity correlated with a differentiation 
blockage [28]. Recently we have shown Spy1 to be an 
important factor regulating stemness in the adult brain and 
human glioma [29]. Spy1 expression drove expansion of 
the glioma population expressing characteristic stem cell 
markers including CD133. Spy1 promoted clonality and 
suppressed multilineage differentiation potential in human 
glioma. Mechanistically, our data demonstrated that Spy1 
is an essential driver of symmetric division of the CD133+ 
population in human glioma. Neuroblastoma TICs share 
many of the hallmark characteristics found in glioma [13, 
15, 30] and the CD133+ population in neuroblastoma 
patient and cell line samples increases clonal expansion 
and tumourigenicity [30]. Hence, we sought to determine 
if Spy1 plays a driving role in neuroblastoma TIC 
populations. 
 This study investigated the role of Spy1 in 
proliferation, self-renewal and differentiation of 
human neuroblastoma cell lines. We find that Spy1 
overexpression in the N-type neuroblastoma SH-SY5Y 
cells results in significantly upregulated proliferation 
and resistance to the 13-cis-Retinoic Acid (RA)-induced 
differentiation. Interestingly, Spy1 overexpressing cells 
demonstrated increased self-renewal in a neurosphere 
formation assay and upregulation of markers indicative of 
the multipotency. The forced upregulation of Spy1 levels 
conferred prolonged clonality and survival to serially 
subcultured spheres whereas downregulation of Spy1 
levels resulted in decrease in tumorsphere number. Our 
data reveals that Spy1 is implicated in regulating CD133+ 
neuroblastoma cell populations. The obtained data 
demonstrates a role for an atypical cell cycle mechanism 
in driving tumourigenicity of neural crest stem cells. 
Importantly, this mechanism has strong implications in 
regulating resistance in at least subsets of neuroblastoma. 
Determining how to block the atypical activation of 
CDKs may prove a valuable therapeutic direction for 
neuroblastoma. 
RESULTS
Endogenous levels of Spy1 are downregulated 
during RA-induced differentiation in 
neuroblastoma
To determine how Spy1 is expressed through 
differentiation in neural progenitor cells human 
neuroblastoma SH-SY5Y cells, were induced to 
differentiate over several days using RA. Cells were 
scored as differentiated when the neurite length exceeded 
twice the size of the cell body. Spy1 protein levels were 
abruptly depleted upon addition of RA, with levels 
being significantly depleted between 16-48 hours post-
differentiation (Fig. 1A). This occurs concurrent with an 
upregulation of the differentiation marker GAP43 and a 
downregulation of the stemness marker Nestin (Fig. 1A; 
lower panel). QRT-PCR analysis upon RA stimulation 
revealed that endogenous SPDYA expression levels were 
significantly downregulated by 48 hours after the addition 
of RA (Fig. 1B). Kinase assays showed that in vitro CDK2 
kinase activity declines in parallel with Spy1 expression 
levels (Fig. 1C).
Stable overexpression of Spy1 causes delayed 
neural differentiation
We tested a panel of neuroblastoma cell lines for 
Spy1 protein expression levels (Fig. 2A). It was noted 
that SH-SY5Y cells had significantly lower levels of Spy1 
than levels found in CHLA15, CHLA20 or BE(2)C cells. 
This correlated with protein levels of the oncogene c-Myc, 
known to transcriptionally upregulate Spy1 levels [32]. 
To determine the effect of abnormal elevation of Spy1 
protein on differentiation in neuroblastoma, Spy1 or an 
empty vector control were stably overexpressed in the 
SH-SY5Y cells. SH-SY5Y-WT (expressing empty vector) 
and SH-SY5Y-Spy1 (Spy1 overexpressing) cell lines 
were induced to differentiate and observed over a 72 hour 
time course. By 72 hours post-differentiation over 75% 
of control cells successfully differentiated while no signs 
of differentiation were visible in the Spy1 overexpressing 
cells (Fig. 2B; right panel). To determine whether effects 
could be due to the known proliferative effects of Spy1, 
cell numbers, BrdU incorporation and PCNA staining was 
conducted (Fig. 2D &2E). At 96 hours post-differentiation 
SH-SY5Y-Spy1 cells continued to proliferate, while SH-
SY5Y-WT cells had significantly reduced proliferation, 
indicative of terminal differentiation (Fig. 2C). This was 
also demonstrated by incorporation of BrdU (Fig. 2D) 
and PCNA (Fig. 2E). In each assay Spy1 overexpressing 
cells continued to synthesize DNA and cycle at 72 hours 
post-differentiation while over 50% of control cells enter 
quiescence by 48 hours post-differentiation. Interestingly, 
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qRT-PCR of cells overexpressing Spy1 in the presence 
of differentiation stimuli revealed significantly higher 
levels of the neural stem cell (NSC) marker Nestin (Fig. 
2F) and significantly lower expression of the neuronal 
differentiation marker, growth associated protein 43 
(GAP43) (Fig. 2G), than control counterparts. 
Spy1 regulates self-renewal in neuroblastoma cells
The pool of multipotent NSCs can be purified from 
heterogeneous cell population utilizing a neurosphere 
formation assay. Unlike neural progenitor cells with 
limited proliferative potential, only highly proliferative 
multipotent NSCs can retain the ability to self-renew 
and produce neurospheres that can be passaged in a 
long term culture [33]. Additionally, neurospheres 
derived through this assay retain the capacity to express 
GAP43 and glial fibrillary acidic protein (GFAP) upon 
differentiation conditions [34]. SH-SY5Y neuroblastoma 
cells have been previously shown to express markers of 
typical neural crest stem cells [35, 36], and to contain 
populations of self-renewing, multipotent tumour cells 
[30, 37]. Interestingly, we found that endogenous levels 
of Spy1 were significantly elevated in cells cultured 
as neurospheres when compared to monolayer culture, 
supporting the endogenous requirement for this protein in 
maintaining multipotency (Fig. 3A). We investigated the 
influence of Spy1 overexpression on self-renewal in SH-
SY5Y cells cultured as neurospheres. Spy1 overexpressing 
cells almost doubled the number of neurospheres as 
compared to controls (Fig. 3B). Increases in neurosphere 
number were significant for neurospheres of a diameter 
smaller than 100µm; however, there was no significant 
increases seen for neurospheres larger than 100µm (Fig. 
3C), notably cultures were carried out in a flat dish and not 
in aggregate culture [38]. Serial passaging of neurospheres 
demonstrated that Spy1 overexpressing populations had 
enhanced longevity over control neurospheres (Fig. 3D). 
Spy1 regulation of stemness and neural lineage 
commitment is controlled by extracellular 
microenvironment
Given the environmental differences seen with 
Spy1 expression in neurosphere culture, corresponding 
passages of SH-SY5Y-WT or SH-SY5Y-Spy1 cells were 
cultured either in monolayer or as neurospheres and gene 
expression was analyzed. Expression of the pluripotency 
marker Oct-4 (Fig. 4A) and the stem cell marker BMI1 
(Fig. 4B) were significantly elevated by Spy1 when 
cultured as neurospheres but not in monolayer culture. 
Spy1 expression significantly elevated the expression of 
glial progenitors and stem-like TIC markers (Fig. 4C-F). 
Specifically, Spy1 enhanced expression of the gene for the 
glial progenitor marker OLIG2 (Fig. 4C), the astrocyte-
specific marker GFAP (Fig. 4E) and the TIC marker 
CD133 (Fig. 4F). Spy1 also enhanced expression of the 
gene for fibronectin (FN1), which has been shown to 
mediate invasiveness and cell survival in other types of 
neural derived tumours (Fig. 4D) [39-41].
Figure 1: Spy1 protein levels are tightly regulated 
during neuroblastoma progenitor fate decisions. (A) 
SH-SY5Y cells differentiated in 13-cis Retinoic Acid (RA) 
(2µM) and assayed at the indicated times. Differentiation was 
recorded by phase contrast inverted microscopy (upper panel) 
and cell lysates were analysed by SDS-PAGE (lower panel). 
Neuronal differentiation was confirmed by detection of GAP43 
expression. α-Tubulin was used as a loading control. Scale bar, 
50 µm. (B) SPDYA expression was assessed over a differentiation 
time course in SH-SY5Y cells by qRT-PCR. Vehicle-treated 
cells were used as a control. Results are presented as mean ± 
s.d. for triplicate samples from a representative experiment. n=4, 
**p < 0.01 (Student’s t-test). (C) CDK2 activity was analyzed 
at the indicated time points post RA treatment in SH-SY5Y 
cells. Vehicle treated cells were used as a control. Phosphor-
imaging analysis is demonstrated as Density Light Units (DLU) 
/mm2 (upper panel). Lower panel depicts a representative 
phosphorimage. Results are presented as mean ± s.d of a 
representative experiment. n=2, *p < 0.05 (Student’s t-test).
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Figure 2: Spy1 overexpression abrogates neuronal differentiation of neuroblastoma. (A) A series of neuroblastoma cell lines 
probed for Spy1 expression by SDS-PAGE One representative blot of 3 is depicted (left hand panel). Densitometry values are presented 
as the mean of Integrated Density Values (IDV) Spy1/Actin over 3 experiments (right panel). *p<0.05. (B-G) SH-SY5Y cell line was 
generated by stably expressing flag-tagged Spy1 (SH-SY5Y-Spy1) and empty vector (SH-SY5Y-WT). Cells were differentiated using 2µM 
13-cis-Retinoic Acid (RA). (B) Morphology over a time course was documented using inverted phase contrast microscopy (left panel). 
Differentiation was scored according to axon length, and the ratio of differentiated cells to total cell number was calculated (right panel). 
Control bars (hollow), Spy1 overexpressing (black bars). Values are mean ± s.d. n=3; *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s 
t-test). Scale bar, 50 µm. (C) Cells were seeded at the density 0.5 x104 cells/ml and differentiated using 2µM RA. Cells were harvested 
and subjected to the trypan blue analysis at indicated times. Representative data are shown as mean ± s.d. n=3, **p < 0.01, ***p < 0.001. 
(D) SH-SY5Y cells were subjected to BrdU incorporation along the RA-induced differentiation time course. Immunocytochemistry was 
conducted at 48 hours and 72 hours. PI was used as a nuclear counterstain (not shown). Scale bar, 100µm. (E) PCNA negative cells and total 
cell number were scored in 3 different fields of view at 48hours and 72hours time points. PCNA negative cells are expressed as a percentage 
of total cell number at each time point. Data are shown as mean ± s.d; n=2. (F & G) Expression levels of (F) Nestin and (G) GAP43 were 
analyzed by qRT-PCR in SHSY5Y-WT (WT) and SH-SY5Y-Spy1 (Spy1) along differentiation time-course. Representative data are shown 
as mean ± s.d. n=3; *p < 0.05 (E) and ***p < 0.001 (F).
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Depletion of Spy1 in neuroblastoma decreases cell 
proliferation and clonality
Given the heterogeneity of tumours and reported 
populations of cancer stem cells in neuroblastoma we 
addressed the role of Spy1 in stemness properties of cell 
lines characterized by higher Spy1 protein (Fig. 2A). 
Spy1 levels were depleted in heterogeneous populations 
of the CHLA-20 and CHLA-15, both shown to contain 
high endogenous levels of Spy1 (Fig. 2A). CHLA-20 line 
contains a pool of CD133+/CD34+/Nestin+ TICs [30] 
and both CHLA-20 and CHLA-15 cell lines are resistant 
to conventional chemotherapy [42]. Spy1 knock-down 
using two different shRNA constructs caused significant 
decrease of CHLA-15 and CHLA-20 cell proliferation 
(Fig. 5A, left & right panel respectively) and increase 
in the levels of GAP-43 neuronal marker mRNA levels 
(Fig. 5B). To determine the role of Spy1 in self-renewal 
of these cells we subjected Spy1 knockdown cells to 
neurosphere formation assay. A decrease in the number 
of spheres formed in both cell lines was noted, although 
this was not significant (Fig. 5C, left & right panel). The 
downregulation of Spy1 was followed by a significant 
decrease in CD133 in both CHLA-15 and CHLA-20 cell 
lines, and a significant decline in c-MYC mRNA levels 
in CHLA-15 cells (Fig. 5D). These results demonstrate 
that Spy1 downregulation is required for neuronal 
differentiation to take place in heterogeneous populations 
of neuroblastoma cells and support that Spy1 is required 
Figure 3: Elevated levels of Spy1 protein promote 
neuroblastoma progenitor self renewal. (A) SH-SY5Y 
cells cultured as neurospheres (NS) or in monolayer (ML) 
were harvested and SPDYA expression levels determined by 
qRT-PCR. Data shown is mean ±s.d, ***p < 0.001. (Student’s 
t-test, n=3). (B-D) SH-SY5Y-WT and SH-SY5Y-Spy1 cells 
were grown in neurosphere assays. (B) Morphology of cultures 
by light microscopy (left panels). Scale bar, 100 µm. Spheres 
were passaged every 6-7 days and the neurosphere formation 
efficiency was quantified as a number of spheres relative to the 
total number of the cells seeded (right panel). Representative 
data are shown as mean ±s.d. of triplicates from three 
independent experiments, **p < 0.01 (Student’s t-test; n=3). 
(C) Neurospheres maintained in culture for 14 days were scored 
according to diameter. Values presented as mean ±s.d. of two 
independent experiments, **p < 0.01. (Student’s t-test). (D) 
Primary, secondary and tertiary neurospheres were subjected to 
MTT assay. The obtained absorbance at 590nm was corrected 
for background absorbance. Data shown is mean ±s.d, *p < 0.05 
(Student’s t-test; n=2).
Figure 4: Spy1 regulation of stemness and neural 
lineage commitment is controlled by extracellular 
microenvironment. (A-F) SH-SY5Y control cells (WT) or 
overexpressing Spy1 (Spy1), cultured in monolayer (ML) or 
as neurospheres (NS). mRNA levels were analysed using qRT-
PCR. Expression levels of (A) OCT-4, (B) BMI1, (C) OLIG2, (D) 
FN1, (E) GFAP, and (F) CD133. Representative data are shown 
as mean ±s.d. of triplicates from three independent experiments, 
*p < 0.05, **p < 0.01 (Student’s t-test).
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Figure 5: Depletion of Spy1 in neuroblastoma decreases cell proliferation and clonality. (A) Proliferation kinetics of CHLA-
15 (left) and CHLA-20 (right) cells infected with two shRNA constructs against Spy1 (pLKO-shSpy1#1, pLKO-shSpy1#2) or scrambled 
control (pLKO-scrambled). (B) GAP-43 expression in pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKO-scrambled CHLA-15 and CHLA-20 
cells. (C) Number of neuroblastoma tumorspheres formed by CHLA-15 (left) or CHLA-20 (right) cells infected with pLKO-shSpy1#1, 
pLKO-shSpy1#2 or pLKO-scrambled. (D) CD133 (left) and c-MYC (right) expression in pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKO-
scrambled CHLA-15 and CHLA-20. (A-D) Data is expressed as mean ±s.d. of triplicates from at least three independent experiments, *p 
< 0.05, **p < 0.01, ***p<0.001 (Student’s t-test).
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for maintaining proliferation and aspects of stemness 
characteristics in neuroblastoma TICs. 
Clonal properties of CD133+ populations of 
neuroblastoma depend on Spy1
To test the hypothesis that Spy1 is involved 
in regulating the CD133+ subpopulation within 
neuroblastoma, as previously determined in glioma 
[29], we sorted CHLA-15 cells for CD133 and subjected 
negative and positive populations to neurosphere formation 
assays (Fig. 6A). We found no significant difference in the 
overall number of the spheres formed between CD133+ 
and CD133- populations (data not shown), however 
CD133+ populations formed significantly more spheres 
of a smaller size, while CD133- populations formed larger 
spheres (Fig. 6B). When Spy1 expression was driven in 
the CD133- population more spheres, particularly of the 
smaller size, were formed (Fig. 6C, left panel). Spy1 
overexpression in this population correlated with an 
increase in the levels of CD133, c-MYC and Ki67, TIC 
and proliferation marker levels in CD133- cells (Fig. 6E). 
In opposition to this, Spy1 knockdown in CD133+ cells 
(Fig. 6C, right panel) resulted in significant decline in 
the number of spheres formed (Fig. 6D; right panel) and 
decreased expression levels of Ki67 and c-MYC (Fig.6F). 
We were not able to amplify CD133 in Spy1 knockdown 
CD133+ samples (not shown). 
Overall, our results revealed that Spy1 is a necessary 
driver of proliferation and stem-like characteristics 
in neuroblastoma, particularly in the CD133+ TIC 
population. Elevated levels of Spy1 in neuroblastoma 
populations suppresses differentiation and promotes TIC 
characteristics. 
DISCUSSION
Inappropriate differentiation of immature cells 
within the ganglionic lineage is thought to drive 
neuroblastoma [2-4]. Indeed, the heterogeneous 
populations of diverse progenitor cells, seen to exist 
within the tumour mirror, neural crest plasticity [12-14]. 
Multiple studies over the years have attempted to elucidate 
the molecular basis behind the differentiation processes 
of neuroblastoma. Diverse agents, growth factors and 
differentiation protocols have been proposed [43-46]; 
however, the information about the role of the cell cycle 
control in neuroblastoma remains insufficient. We report 
for the first time that an atypical G1 phase regulator, 
Spy1, is implicated in differentiation and self-renewal of 
neuroblastoma cells. 
We utilized the SH-SY5Y cell line of an established 
N-cell phenotype that is blocked at the precursor stage 
of neuronal development. We find that endogenous 
Spy1 levels are reduced during cell differentiation and 
that preventing this downregulation also prevents RA-
induced differentiation. Overexpression of Spy1 resulted 
in enhanced self-renewal and longevity of neuroblastoma 
cells cultured in a neurosphere formation assay. Spy1 
levels were also significantly elevated in self-renewing 
neurosphere populations, as compared to cells cultured as 
a monolayer. Collectively, this suggests a potential role 
of the Spy1 protein as a stabilizer of proliferation among 
cell populations of higher hierarchy, namely progenitors 
and TICs. Spy1 has demonstrated roles in spinal cord 
regeneration [47], it was found to possess stem-like 
qualities in the developing mammary gland [32] and in 
the subventricular zone stem cells in the adult brain [29], 
supporting a general role for Spy1 in select populations of 
adult stem or progenitor cells. 
Spy1 is a direct activator of CDK2 [48], and 
Spy1 can indirectly activate CDK2 by promoting the 
degradation of the CDK inhibitor p27Kip1 [20]. Dobashi et. 
al. demonstrated that a decrease in CDK2 kinase activity 
must occur in order to support functional differentiation 
[49] and others have demonstrated that p27Kip1 levels 
accumulate during neuronal cell differentiation [50]. 
Interestingly, suppression of CDK2 activity is required for 
reduced proliferation and survival of the primary neural 
crest derived tumour and its inhibition was demonstrated 
to be synthetic lethal in MYCN overexpressing 
neuroblastoma [26, 51]. Spy1 direct interactions with 
p27Kip1 promote the phosphorylation on Thr-187 of p27Kip1, 
a modification that is required for its ubiquitination by 
SCFSkp2complex and its subsequent proteolysis [52-
54]. High expression of the Skp2 component of the 
SCFSkp2 ligase was included in the genetic signature of 
aggressive stages of neuroblastoma. Skp2 overexpression 
correlated with p27Kip1 protein downregulation and poor 
patient prognosis [55, 56]. Hence, Spy1-mediated CDK2 
activity may affect the outcome of patients with Skp2 
overexpression. 
We observed a differential effect of Spy1 on 
neuroblastoma cells when grown in neurosphere culture, 
versus the general population of cells grown in monolayer 
culture. In neurosphere culture Spy1-induced expression 
of the progenitor and multipotency markers BMI11 and 
OCT-4, respectively. Both BMI1 and OCT-4 were shown 
to exert their functions in the other neural tumours by 
preventing cellular differentiation and contributing 
to their growth and progression [57, 58]. Hence, this 
data supports the hypothesis that Spy1 may function in 
promoting the growth of highly undifferentiated cells in 
neuroblastoma. When cells were in monolayer, however, 
Spy1 promoted expression of glial progenitors such as 
GFAP and OLIG2. SH-SY5Y cells were demonstrated 
previously to contain a minute pool of highly clonogenic 
S-cells [59] that are also characterized by expression of 
glial markers [13]. Thus, forced expression of Spy1 can be 
speculated to contribute to the expansion of self-renewing 
cell populations within the heterogeneous tumour. We 
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Figure 6: Clonal properties of CD133+ populations of neuroblastoma depend on Spy1. (A) CHLA-15 cells sorted for 
CD133. Expression levels of CD133 depicted in CD133+ vs. CD133- population. (B) CD133- and CD133+ populations analyzed for the 
number and size of spheres formed. (C; left) Spy1 mRNA levels in CD133- cells subjected to Spy1 overexpression. (C; right) CD133+ 
population subjected to knockdown control (pLKO-scrambled) or Spy1 knockdown (pLKO-shSpy1 #1 and #2). (D) Number and size 
of tumorspheres formed in CD133- cells overexpressing Spy1 (left) or CD133+ Spy1 knockdown cells (right). (E) CD133- population 
overexpressing Spy1 assessed for expression of CD133, Ki67 or c-MYC. All genes are expressed relative to GAPDH and pEIZ-Control(cntl) 
genes are normalized to 1. pEIZ-Spy1 expression is shown relative to pEIZ-Control. (F) Ki67 (left) and MYC (right) expression in CD133+ 
cells expressing pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKO-scrambled. (A-F) Data is expressed as mean ±s.d. of triplicates from three 
independent experiments, *p < 0.05, **p < 0.01, ***p<0.001 (Student’s t-test).
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show for the first time that the proliferation and clonal 
expansion of CD133+ neuroblastoma TICs relies on 
Spy1, and that Spy1 overexpression increases while 
its knockdown leads to decrease in c-MYC expression 
levels in this population. Consistently our results show 
that c-myc protein levels correlate with Spy1 expression 
in all neuroblastoma cell lines tested. We have reported 
previously that Spy1 expression is regulated downstream 
of c-myc [32]. Whether c-myc regulation takes place in 
neuroblastoma requires further investigation. These data 
support a potential role for Spy1 in maintaining stem-
like TIC population in neuroblastoma. Careful analysis is 
required to determine if Spy1 manipulation affects specific 
subpopulations differently.
METHODS
Cell lines
Using BBS/CaCl2 delivery (pH 7.05, 37°C and 3% 
CO2) PT67 packaging cells were transiently transfected 
with the DNA construct of choice. Following an 8 hour 
incubation (37°C and 3% CO2) media was changed, and 
cells were allowed to recover at 37°C and 5% CO2. 24 
hours later cell media containing the virus were harvested, 
centrifuged for 5 minutes at 2,000 g and filter sterilized 
using a 0.45 µm filter. An overnight amplification (P2) 
was also collected, filter sterilized and stored at -80°C. 
Cells were infected with P2 virus at ~70-80% confluency 
and incubated overnight in 1:2 volume/volume virus to 
cell media ratio containing polybrene (25 µg/ml). Media 
was changed the next day and 24 hours later infected 
cells were selected in media containing 600 µg of G418. 
Individual colonies, as well as mixed populations of 
cells, were maintained and the incorporation of cDNA 
was checked using genomic DNA and primers spanning 
the exon-exon junctions. SH-SY5Y cells were obtained 
from ATCC. Stable SH-SY5Y lines were selected and 
cells were maintained in media containing 200 µg/mL of 
G418. CHLA-15 and CHLA-20 cell lines were obtained 
from Children Oncology Group repository (University 
of Texas). Infected cells were selected with 1ug/ml of 
Puromycin.
Differentiation assays
SH-SY5Y cells were grown on 60 mm or 100 mm 
plates to 60% confluency. 13-cis- Retinoic Acid (2 µM) 
was added to SH-SY5Y growth media to induce neurite 
outgrowth. Cover-slips and cell pellets were harvested 
each day, and control samples (kept in growth media) were 
harvested on day 1. Cells were pelleted by centrifugation 
at 13,000 rpm for 15 minutes at 4°C, supernatant was 
removed, and pellets were stored at –20°C until use. 
Cell pellets were lysed in 0.1% NP-40 lysis buffer (0.1% 
NP-40, 20 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 100 
mM sodium chloride) for 1 hour, with mixing every 10 
minutes. Samples were centrifuged again at 13,000 rpm 
for 15 minutes at 4°C to remove cell debris, and stored 
at –20°C until use. Imaging was done on the AxioSkope2 
Plus microscope (Zeiss) using Northern Eclipse computer 
software. 
BrdU assay and fluorescent detection
SH-SY5Y cells were grown on cover slips in 60 mm 
culture dishes. Over a differentiation time course BrdU 
(Cat# 550891; BD Sciences) was added to the media to 
a final concentration of 10 µM, incubated for 30 minutes 
and then cover slips were harvested. The cell culture 
density never exceeded 2x106 cells/ml. Cells were fixed 
with 70% ethanol for 30 minutes at room temperature 
followed by incubation with 0.07N NaOH for 2 minutes 
and neutralization in PBS, pH 8,5. Primary antibody 
against BrdU (Cat# 347580, BD Sciences) was applied 
for 30 minutes in humidified chamber. The cells were 
washed 3 times with PBS and incubated with secondary 
antibody conjugated to Alexa- 488 fluorophore (A11059, 
Invitrogen) for 30 minutes at room temperature. Cell 
nuclei were labeled with Propidium Iodide (0.04 µg/ml) 
for 1 minute. Cover slips were washed with water and 
mounted on microscope slides with Vectashield mounting 
medium. Imaging was conducted on Eclipse E800 
microscope (Nikon, Japan)
Proliferation kinetics
Cells were seeded at the density of 0.5 x104 cells/
ml in 6 well plates or at the density 1.6 x105/ml in 6 cm 
tissue culture dishes. The medium and growth factors 
were changed daily and proliferation kinetics was 
determined by cell counting at the indicated time points 
using hemocytometer or TC100 Automated Cell Counter 
(BioRad). 
MTT assay
Primary, secondary and tertiary neurospheres were 
dissociated and 104 cells were seeded in 100 µl of media 
in 96 well anti adhesive plates. 20 µl of 5 mg/ml MTT 
solution in PBS were added to each well and incubated 
for 4 hours. 100 µl of extraction buffer was added for 2 
hours to dissolve the formazan crystals and the absorbance 
at 590 nm was assessed using Victor plate reader (Perkin 
Elmer).
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Neurosphere formation assay
Cells were seeded into Ultra Low Cluster Plates 
(Corning Life Sciences, cat. no.3471) at 5x104 (SH-
SY5Y; 6-well dishes) or 2x104 (CHLA-15 and CHLA-
20: 24-well dishes). The serum-free culture medium 
DMEM/F12 (Sigma) was supplemented with 60 µM 
putrescin, 20 nM progesterone, 5 µg/ml insulin, 100 
µg/ml transferrin, 30 nM sodium selenite and 6 µg/ml 
glucose. Growth factors: human Epidermal Growth Factor 
(Gibco) and basic Fibroblast Growth Factor (Sigma) were 
added every 48-72 hours in final concentration of 20 ng/
ml and 10 ng/ml in media, respectively. Differentiation 
of primary neurospheres was obtained as described 
previously [31]. Neurospheres were transferred on Poly-
D-Lysine coated cover-slips placed in 6 well plates and 
allowed to attach overnight in a drop of culture medium. 
To induce differentiation wells were filled with culture 
medium supplemented with 2% FBS. After 7-14 days the 
cover-slips were examined for neural differentiation and 
subjected to immunocytochemistry. To study secondary 
neurosphere formation, cells were seeded into 24 or 96-
well plates at 102 cells per well. After 6-7 days the number 
and size of the neurospheres formed were recorded. The 
neurosphere diameter was assessed optically with an 
object micrometer. 
Western blotting
Protein samples were prepared with 4 times sample 
buffer (10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2% SDS, 
0.01 mg/mL bromophenol blue, 2% β-mercaptoethanol), 
and boiled for 5 minutes at 95-105 °C. Samples were 
loaded onto 10% polyacrylamide gels and ran at 110 volts 
for 4.5 hours. Proteins were then transferred to PVDF 
membranes through semi-wet transfer at 30 volts for 2.5 
hours. Membranes were blotted in 3% milk for 2 hours to 
overnight. Primary antibodies were incubated overnight at 
4°C (except for Actin mouse, which was incubated 1 hour 
at room temperature). Antibody concentrations used were 
as follows: Actin MAB150 1R, (Chemicon- Millipore; 
1:1000), -Tubulin TU-02 (Sigma; 1:1000), CDK2 mouse 
D-12 (Sigma 1:1000), CDK2 rabbit M2 (Sigma; 1:500), 
human Spy1 (Novus; 1:1000-1:10000, Abcam; 1:1000), 
p27Kip1 NA35 (Calbiochem 1:100), GAP43 G9264 (Sigma 
1:1000), GFAP G4546 (Sigma 1:1000), Nestin G-20 
(Santa Cruz 1:1000). Membranes were washed with TBST 
3 times for 5-10 minutes, followed by 1 hour incubation 
in secondary antibody (mouse, rabbit or goat – 1:10000) 
at room temperature. Membranes were then washed with 
TBST 3 times for 15 minutes and were visualized using 
FluorChemHD2imaging system (Alpha Innotech). 
Immunoprecipitation and CDK2 kinase assay
Bradford assays were performed to ensure 
equal protein loading, and 100-250 µg of protein was 
immunoprecipitated from SH-SY5Y cell lysates. Protein 
was incubated with 5 µL of CDK2-mouse antibody 
overnight at 4°C. The following day, 5 µL of protein A 
sepharose beads were added to the samples and incubated 
for 1 hour at 4°C. Samples were then washed three times 
with NP-40 lysis buffer at 4°C and aspirated to a final 
volume of 25µl. CDK2 kinase assays were performed in 
kinase buffer (50 mMTris-Hcl pH 7.5, 10 mM MgCl2, 1 
mM DTT, 20 mM EGTA) and 0.5 µCi/µL [γ-32P]ATP- 
~3,000 Ci/mmol obtained from Perkin Elmer. 4 µg of 
Histone H1 was added to each 25 µl immunoprecipitated 
sample (described above) incubated with 25 µL of 2 
times kinase buffer. Samples were incubated at 30°C 
for 30 minutes, followed by the addition of 25 µL of 4 
times sample buffer. Samples were boiled for 5 minutes 
at 95-105°C and loaded onto 10% polyacrylamide gels. 
SDS-PAGE and transfer were performed as described 
above. Membranes were exposed using a Cyclone 
PlusPhosphoimager (Perkin Elmer), and analyzed using 
OptiQuant software. 
qRT-PCR
Total RNA was extracted from cells or tissues 
utilizing RNAeasyPlus Mini Kit (Qiagen) and reverse 
transcribed using 200U Superscript II (Invitrogen), 0.5 
µg OligodT’s and 0.5 µg random nanomers (Sigma) 
according to the manufacturer instructions. For each 
experiment the samples were reverse transcribed at the 
same time and cDNA was stored at -20oC. Real time 
PCR with SYBR green (Applied Biosystems) fluorescent 
detection and 200-250 nM of each primer was performed 
using ABI Prism 7300 or Viia7 thermocycler. Primers 
were designed using Primer Express software. GAPDH 
was used as the endogenous control. Data was analyzed 
using ABI 7300 or Viia7 software and represented as log10 
relative quantification (RQ) or RQ relative to control. 
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